













# CRUK CENTRE FOR DRUG DEVELOPMENT

## SMALL MOLECULE THERAPIES

AGENT/TRIAL	TARGET/TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					PROJECT INITIATION	EXPLORATORY	PRE-CLINICAL	TRIAL SET UP	PHASE I	PHASE II
DETERMINE - Agent tbc	Target tbc	 The University of Manchester 	Rare adult, paediatric & TYA cancers	Phase II	→					
BT1718	MT1-MMP		Solid, lung	First in class (closed)	→	→	→	→	→	
HTL0039732	EP4		Solid, colorectal, prostate, gastric, oesophageal, renal	First in human	→	→	→	→	→	
LY3143921	Cdc7		Solid, colorectal, ovarian, lung	First in human (closed)	→	→	→	→	→	
TT702 (CURATE)	adenosine A <sub>2B</sub> R		Solid	First in human	→	→	→	→	→	
DETERMINE - Alectinib - Dabrafenib/ Trametinib - Entrectinib	ALK, BRAF, MEK, ROS1, TKI, TRK	 The University of Manchester  	Rare adult, paediatric & TYA cancers	Phase II Phase II combination Phase II	→	→	→	→	→	→
DETERMINE - Capmatinib - Vemurafenib/ Cobimetinib	BRAF, cMET, HGFR, MAP, MEK	 The University of Manchester  	Rare adult cancers	Phase II Phase II combi (closed)	→	→	→	→	→	→

